Patents by Inventor Scott Louis Cohen

Scott Louis Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20230183286
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: August 16, 2022
    Publication date: June 15, 2023
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 11466048
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 11, 2022
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20200190132
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy WHITE, Sarah Louise WILLIAMS, Jun YUAN, Frederic ZECRI
  • 3? end caps, 5? end caps and combinations thereof for therapeutic RNA
    Patent number: 10676499
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: June 9, 2020
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Williams, Jun Yuan, Frederic Zecri
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 10112963
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA
    Publication number: 20180002368
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids arc disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Application
    Filed: December 16, 2015
    Publication date: January 4, 2018
    Inventors: David BARNES-SEEMAN, Scott Louis COHEN, John Louis DIENER, Christian GAMPE, James ROACHE, Amy WHITE, Sarah WILLIAMS, Jun YUAN, Frederic ZECRI
  • Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
    Patent number: 9789118
    Abstract: The present invention provides compounds of formula (IV); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (IV), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: October 17, 2017
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Gregory Raymond Bebernitz, Kevin Clairmont, Scott Louis Cohen, Robert Edson Damon, II, Robert Francis Day, Stephanie Kay Dodd, Christoph Gaul, Hatice Belgin Gulgeze Efthymiou, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Kai Lin, Justin Yik Ching Mao, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Su Liansheng
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20170015688
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin RIGEL
  • 2,3,5-trisubstituted thiophene compounds and uses thereof
    Patent number: 9498483
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Jiping Fu, Lei Shu, Rui Zheng
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 9480693
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 1, 2016
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20150374726
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin RIGEL
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 9163040
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: October 20, 2015
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof
    Publication number: 20150224109
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: Novartis AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Jiping FU, Lei SHU, Rui ZHENG
  • 2,3,5-trisubstituted thiophene compounds and uses thereof
    Patent number: 9040690
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: May 26, 2015
    Assignee: Novartis AG
    Inventors: David Barnes, Scott Louis Cohen, Jiping Fu, Lei Shu, Rui Zheng
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20140228323
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin Rigel
  • BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF
    Publication number: 20140171363
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Gregory Raymond BEBERNITZ, Kevin CLAIRMONT, Scott Louis COHEN, Robert Edson DAMON, II, Robert Francis DAY, Stephanie Kay DODD, Christoph GAUL, Hatice Belgin GULGEZE EFTHYMIOU, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Kai LIN, Justin Yik Ching MAO, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, SU Liansheng
  • Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
    Patent number: 8697739
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: April 15, 2014
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Gregory Raymond Bebernitz, Kevin Clairmont, Scott Louis Cohen, Robert Edson Damon, Robert Francis Day, Stephanie Kay Dodd, Christoph Gaul, Hatice Belgin Gulgeze Efthymiou, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Kai Lin, Justin Yik Ching Mao, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Liansheng Su
  • 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof
    Publication number: 20130123252
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 21, 2011
    Publication date: May 16, 2013
    Applicant: NOVARTIS AG
    Inventors: David Barnes, Scott Louis Cohen, Jiping Fu, Lei Shu, Rui Zheng
  • Cyclohexane derivatives and uses thereof
    Patent number: 8394858
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: March 12, 2013
    Assignee: Novartis AG
    Inventors: David Barnes, Gregory Raymond Bebernitz, Scott Louis Cohen, Robert Edson Damon, Robert Francis Day, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Herbert Franz Schuster, Wei Zhang
  • Furopyridine compounds and uses thereof
    Patent number: 8324239
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventors: David Barnes, Rajiv Chopra, Scott Louis Cohen, Jiping Fu, Mitsunori Kato, Peichao Lu, Mohindra Seepersaud, Wei Zhang